# Effect of chemoradiotherapy on the dynamics of circulating lymphocyte subsets in patients with non-metastatic nasopharyngeal carcinoma

**Authors:** Lilan Yi, Yinfang Gu, Longhua Guo, Xiaofang Zou, Guowu Wu

PMC · DOI: 10.3389/fonc.2025.1521836 · Frontiers in Oncology · 2025-02-12

## TL;DR

This study examines how chemoradiotherapy affects immune cell levels in non-metastatic nasopharyngeal cancer patients and how these changes relate to treatment response.

## Contribution

The study reveals specific dynamic changes in lymphocyte subsets during chemoradiotherapy and their association with clinical outcomes in NPC patients.

## Key findings

- CD3+CD4+ T cell proportions and absolute counts were higher in complete responders compared to partial responders after CRT.
- CD16+CD56+ NK cell absolute counts were lower in complete responders compared to partial responders after CRT.
- CRT caused dynamic shifts in circulating lymphocyte subsets, with initial decreases followed by increases in absolute counts.

## Abstract

Chemoradiotherapy (CRT) is the primary and most effective treatment for non-metastatic nasopharyngeal carcinoma (NPC), exerting antitumor effects by modulating immune cells. Distinct subpopulations of immune cells exhibit specific sensitivity to CRT. This study aimed to characterize the dynamics of the proportions and absolute counts of peripheral circulating lymphocyte subsets in non-metastatic NPC before and after CRT, and to elucidate their association with clinical responses.

A total of 91 patients with non-metastatic NPC were enrolled. Flow cytometry was employed to detect the expression of CD3, CD4, CD8, CD56, and CD19 on peripheral blood cells. The composition of lymphocyte subsets before treatment, post-completion of CRT, and one month following CRT was retrospectively analyzed. Further, the relationship between the composition of circulating lymphocyte subpopulations and distinguish clinical responses was evaluated.

The proportion of CD3+ T cells showed an initial increase followed by a significant decrease at baseline, post-completion of CRT, and one month following CRT. The proportions of CD3+CD4+ T cells, CD4+/CD8+ ratio, and CD19+ B cells continued to decline at baseline, post-completion of CRT, and one month following CRT, while the proportions of CD3+CD8+ T cells and CD16+CD56+ NK cells progressively increased. The absolute counts of circulating lymphocyte subsets, including CD3+ T cells, CD3+CD4+ T cells, CD3+CD8+ T cells, CD45+, CD19+ B cells, and CD16+CD56+ NK cells, demonstrated a trend of initial decrease followed by an increase at baseline, post-completion of CRT, and one month following CRT. Patients with complete response (CR) and partial response (PR) presented similar dynamic trends in the percentages and absolute counts of circulating lymphocyte subpopulations at baseline, post-completion of CRT, and one month following CRT. The proportions and absolute counts of CD3+CD4+ T cells in CR patients were distinctly higher than those in PR patients at the end of CRT, whereas the absolute counts of CD16+CD56+ NK cells were remarkably lower in CR patients compared to PR patients. The baseline proportion and absolute count of CD19+ B cells, as well as the absolute count of CD3+CD4+ T cells, were significantly higher in CR patients compared with PR patients.

CRT induced dynamic alterations in the peripheral lymphocyte profile of non-metastatic NPC patients. Assessing the variations in the distribution of circulating lymphocyte subsets among patients with different clinical treatment responses will be helpful in developing protocols for the concurrent utilization of immunotherapeutic drugs and CRT.

## Linked entities

- **Proteins:** cd.3 (Cd.3 conserved hypothetical protein), CD4 (CD4 molecule), CD8A (CD8 subunit alpha), NCAM1 (neural cell adhesion molecule 1), CD19 (CD19 molecule), PTPRC (protein tyrosine phosphatase receptor type C), FCGR3B (Fc gamma receptor IIIb)
- **Diseases:** nasopharyngeal carcinoma (MONDO:0015459)

## Full-text entities

- **Genes:** CD8A (CD8 subunit alpha) [NCBI Gene 925] {aka CD8, CD8alpha, IMD116, Leu2, p32}, FCGR3A (Fc gamma receptor IIIa) [NCBI Gene 2214] {aka CD16-II, CD16A, FCG3, FCGR3, FCRIIIA, FcGRIIIA}, PTPRC (protein tyrosine phosphatase receptor type C) [NCBI Gene 5788] {aka B220, CD45, CD45R, GP180, IMD105, L-CA}, CD4 (CD4 molecule) [NCBI Gene 920] {aka CD4mut, IMD79, Leu-3, OKT4D, T4}, NCAM1 (neural cell adhesion molecule 1) [NCBI Gene 4684] {aka CD56, MSK39, NCAM}, CD19 (CD19 molecule) [NCBI Gene 930] {aka B4, CVID3}
- **Diseases:** NPC (MESH:D000077274)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC11861370/full.md

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC11861370/full.md

## References

35 references — full list in the complete paper: https://tomesphere.com/paper/PMC11861370/full.md

---
Source: https://tomesphere.com/paper/PMC11861370